What is BioNexus Gene Lab Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BioNexus Gene Lab's annualizedGross Profit for the quarter that ended in Mar. 2024 was $1.46 Mil.
BioNexus Gene Lab's average Total Assets over the quarter that ended in Mar. 2024 was $11.28 Mil. Therefore, BioNexus Gene Lab's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 12.94%.
BioNexus Gene Lab Gross-Profit-to-Asset % Historical Data
The historical data trend for BioNexus Gene Lab's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Gross-Profit-to-Asset %
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Gross-Profit-to-Asset % Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
BioNexus Gene Lab Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 